Abstract Library

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4580 Improving diagnosis of neuroendocrine tumours using large language models

Introduction: Neuroendocrine tumours (NETs) are a heterogeneous group of cancers that can be difficult to diagnose due to their variable clinical presentation and non-specific symptoms. Accurate diagnosis often requires integrating a wide range of clinical, radiological, and pathological information. Large language models (LLMs) have shown promise in processing and understanding complex medical text, making them a valuable tool for improving diagnostic accuracy in oncology.

Conference:

Presenting Author:

Authors: Tang Z, Chen P, Tang J, Li H, Chen Y,

Keywords: Neuroendocrine Tumour (NET), Large Language Model (LLM), Medical Natural Language Processing (NLP), Clinical Decision Support,

#4522 Leveraging large language models for enhanced diagnosis of neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are a heterogeneous group of cancers that are difficult to diagnose due to their variable clinical presentation and non-specific symptoms. Accurate diagnosis often requires integrating a wide range of clinical, radiological, and pathological information. However, clinicians may struggle to synthesise these diverse data sources effectively. Large language models (LLMs) have shown promise in processing and understanding complex medical text, making them a valuable tool for improving diagnostic accuracy in oncology.

Conference:

Presenting Author:

Authors: Tang Z, Tang J, Cheng F, Li H, Chen Y,

Keywords: Neuroendocrine Tumour (NET), Large Language Model (LLM), Medical Natural Language Processing (NLP), Clinical Decision Support,

#4500 Effectiveness of palbociclib plus letrozole as first line therapy of metastatic breast neuroendocrine carcinoma: A case report

Introduction: Palbociclib plus endocrine therapy is the standard treatment of advanced luminal breast cancer. However, we lack data on its effectiveness in breast neuroendocrine carcinoma (NEC).

Conference:

Presenting Author:

Authors: Saidi M, Aris H, Elyebdri H, Ilham L,

Keywords: breast neuroendocrine carcinoma, CDK4/6 inhibitor, palbociclib, endocrine therapy,

#4499 Impact of early molecular tumour board inclusion on treatment outcomes in neuroendocrine neoplasms: A retrospective double-centre study

Introduction: The treatment of neuroendocrine neoplasms (NENs) is particularly challenging due to the limited availability of standard therapies. While personalised approaches are revolutionising many areas of oncology, their progress in the field of NENs has been comparatively slower. The integration of molecular tumour boards (MTBs) into clinical practice represents a major advance in oncology, even for rare entities such as NENs.

Conference:

Presenting Author: Klaas L

Authors: Barsch M, Graessel L, Metzger P, Klaas L, Schulz L,

Keywords: Neuroendocrine neoplasm, Molecular Tumour Board, personalised medicine, precision oncology, targeted therapy,